Chroma Medicine Stock

chromamedicine.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $262MM

Chroma Medicine leverages genomic medicine to develop therapeutics able to control gene expression. With the ability to target parts of the genome, the goal is relief for patients suffering from severe illnesses. Chroma Medicine was founded in 2021 by Angelo Lombardo Ph.D., Luigi Naldini Ph.D., David Liu Ph.D., and Jonathan Weissman Ph.D. and is headquartered in Boston, MA.

Register for Details

For more details on financing and valuation for Chroma Medicine, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Chroma Medicine.

Register Today


Management Team

Vic Myer Ph.D
Chief Scientific Officer & President
Brett Kaplan MD
Chief Financial and Strategy Officer & Chief Corporate Development Officer

Board Members

Bihua Chen
Cormorant Asset Management
George Golumbeski Ph.D
ARCH Venture Partners
John Maraganore Ph.D
ARCH Venture Partners
Thomas Cahill Ph.D
Newpath Partners

Other companies like Chroma Medicine in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Chroma Medicine raises $135 million for its epigenetic editing therapies
Chroma's approach, known as epigenetic editing, could have broad applications for treating both rare and common diseases.
Chroma bags another 9-digit financing, taking $135M series B to bolster epigenetic-focused platform
A more cautious financing market is evidently no barrier for Chroma Medicine and its epigenetic-focused tech, with the Cambridge, Massachusetts-based biotech bagging $135 million in series B funds to build out its platform.
Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB) comprising renowned leaders in epigenetics, cell and gene therapy, and synthetic biology: Bradley Bernstein, M.D., Ph.D., Paula Cannon, Ph.D., Howard Chang, M.D., Ph.D., and Ahmad (Mo) Khalil, Ph.D.
Updated on: Sep 29, 2023